As director of the BioHub (managed by BioCity, a leading UK bioscience incubator), Ned is responsible for the strategic direction and leadership of the business, and establishing the Manchester Science Partnerships (formerly AstraZeneca) site at Alderley Park as a leading centre of excellence for early stage fast growing life science companies. With proven sector expertise and awareness of market dynamics, Ned has been involved in excess of $250m of equity fund raisings for North American and European companies, including Eyegate Pharma, EffRx, Artielle Immunotherapeutics, Synergy Pharma, Orchid Asia, Zhaopin, and Nexx Systems, which have current market valuations of over $2.0b. Prior to investment banking, Ned conducted primary research in neuropsychopharmacology, psychoneuroimmunology and neuroscience at Yale Medical School and the University of Oxford. Ned is on the advisory board of Alderley Park Ventures, a £5m fund which provides investment for early stages businesses on site. BioCity specialises in the creation and development of life science businesses. It provides homes and access to high-end analytical equipment, shared services, training, business support, and access to investment for new and growing bioscience businesses. Over 250 companies are based in a BioCity business incubator, making the BioCity network one of the largest concentrations of life science businesses in the UK. The 91% survival rate of companies at BioCity Nottingham tangibly demonstrates one of the benefits to a company being located within the BioCity network. In 2012, BioCity established BioCity Scotland, near Glasgow, in 2013 the BioHub at Alderley Park, later MediCity on the Boots campus in Nottingham, and most recently MediCity in Scotland.